# AstraZeneca Plc Lynparza approved in EU for the treatment of germl

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-lynparza-approved-in-eu-for-the-treatment-of-germl/412771668
- Published: 2019-04-10T07:42:09+01:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US
and Canada) today announced the European Commission has approved Lynparza (olaparib)
as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations(
gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-
advanced or metastatic breast cancer.

Under the licensed indication, patients should have previously been treated with
an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless 
they were unsuitable for these treatments. Patients with hormone receptor (HR)-positive
breast cancer should also have progressed on or after prior endocrine therapy, or
be considered unsuitable for endocrine therapy.

> **Dave Fredrickson, Executive Vice President, Oncology, said**: “With this approval,
> Lynparza provides patients throughout the EU with a targeted and oral chemotherapy-
> free treatment option for a difficult-to-treat cancer. It also reinforces the 
> importance of testing for biomarkers including BRCA, hormone receptor and HER2
> expression, helping physicians to make the most informed treatment decisions for
> patients.”
> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, MSD Research Laboratories, said**: “In the OlympiAD trial, which
> supported this approval, Lynparza demonstrated a meaningful improvement in progression-
> free survival compared to chemotherapy in patients with germline BRCA-mutated 
> metastatic breast cancer. We look forward to making this new option available 
> across the EU, where we hope it will improve outcomes for many patients.”

The approval was based on data from the randomised, open-label, Phase III OlympiAD
trial which tested Lynparza vs. physician’s choice of chemotherapy (capecitabine,
eribulin, or vinorelbine). In the trial, Lynparza provided patients with a statistically-
significant median progression-free survival improvement of 2.8 months (7.0 months
for Lynparza vs. 4.2 months for chemotherapy). Patients taking Lynparza experienced
an objective response rate (ORR) of 52%, which was double the ORR for those in the
chemotherapy arm (23%).

This is the third indication for Lynparza in the EU, and AstraZeneca and MSD are
working together to deliver Lynparza as quickly as possible to more patients across
multiple settings. Lynparza has a broad clinical development programme, including
the ongoing Phase III OlympiA which is testing Lynparza as an adjuvant treatment
in patients with gBRCAm HER2-negative breast cancer.

**About OlympiAD**

OlympiAD was a global, randomised, open-label, multi-centre Phase III trial of 302
patients, assessing the efficacy and safety of Lynparza tablets (300mg twice daily)
compared to the physician’s choice of chemotherapy (capecitabine, eribulin or vinorelbine);
205 patients were randomised to receive Lynparza and 97 patients were randomised
to receive chemotherapy. Patients in the OlympiAD trial had germline BRCA1- and/
or BRCA2-mutated, HER2-negative (HR-positive or triple negative) breast cancer and
received Lynparza for treatment in the metastatic setting.

Prior to enrolment, all patients were treated with an anthracycline (unless it was
contraindicated) and a taxane chemotherapy in the neoadjuvant, adjuvant or metastatic
setting. Patients with metastatic breast cancer (71% of patients) had received no
more than two previous chemotherapy treatments for metastatic disease. Patients 
with HR-positive breast cancer had received at least one endocrine (hormonal) therapy(
in the adjuvant or metastatic setting) and had disease progression during therapy,
unless they had disease for which endocrine therapy was considered inappropriate.
Previous treatment with platinum chemotherapy in the neoadjuvant, adjuvant or metastatic
setting was allowed (28% of patients).

The most common adverse reactions (≥20%) in the OlympiAD trial of patients who received
Lynparza were nausea (58%), anaemia (40%), fatigue (including asthenia) (37%), vomiting(
30%), neutropenia (27%), respiratory tract infection (27%), leukopenia (25%), diarrhoea(
21%) and headache (20%). The percentage of patients who discontinued treatment in
the Lynparza arm was 5% vs. 8% in the chemotherapy arm.

**About advanced breast cancer**

Advanced/metastatic breast cancer refers to Stage III and IV breast cancer. Stage
III disease may also be referred to as locally-advanced breast cancer, while metastatic
disease is the most-advanced stage of breast cancer (Stage IV) and occurs when cancer
cells have spread beyond the initial tumour site to other organs of the body outside
the breast. Since there is no cure for the disease, the goal of current treatment
is to delay disease worsening or death.

In 2018, there were an estimated 2.1 million new cases of breast cancer worldwide–
one in four cancer cases among women (24.2%). In Europe the estimated 5-year prevalence
of breast cancer in 2018 was 2,054,887 cases.1 Approximately 30% of women who are
diagnosed with early breast cancer will go on to develop advanced disease.

**About BRCA**

Breast cancer susceptibility genes 1/2 (BRCA1 and BRCA2) are human genes that produce
proteins responsible for repairing damaged DNA and play an important role maintaining
the genetic stability of cells. When either of these genes is mutated, or altered
such that its protein product either is not made or does not function correctly,
DNA damage may not be repaired properly, and cells become unstable. As a result,
cells are more likely to develop additional genetic alterations that can lead to
cancer.

**About Lynparza**

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment
to block DNA damage response in cells/tumours harbouring a deficiency in homologous
recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2. Inhibition 
of PARP with Lynparza leads to the trapping of PARP bound to DNA single-strand breaks,
stalling of replication forks, their collapse and the generation of DNA double-strand
breaks and cancer cell death. Lynparza is being tested in a range of tumour types
with defects and dependencies in the DDR.

Lynparza, which is being jointly developed and commercialised by AstraZeneca and
MSD, is approved for multiple indications in advanced ovarian cancer and metastatic
breast cancer and has been used in over 20,000 patients worldwide. On 26 February
2019, AstraZeneca and MSD announced that Lynparza became the first PARP inhibitor
to demonstrate benefit in gBRCAm metastatic pancreatic cancer in the Phase III POLO
trial.

Lynparza has the broadest and most advanced clinical trial development programme
of any PARP inhibitor, and AstraZeneca and MSD are working together to understand
how it may affect multiple PARP-dependent tumours as a monotherapy and in combination
across multiple cancer types. Lynparza is the foundation of AstraZeneca’s industry-
leading portfolio of potential new medicines targeting DDR mechanisms in cancer 
cells.

**About the AstraZeneca and MSD strategic oncology collaboration**

In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US, known as MSD
outside the United States and Canada, announced a global strategic oncology collaboration
to co-develop and co-commercialise Lynparza, the world’s first PARP inhibitor and
potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types. 
Working together, the companies will develop Lynparza and selumetinib in combination
with other potential new medicines and as a monotherapy. Independently, the companies
will develop Lynparza and selumetinib in combination with their respective PD-L1
and PD-1 medicines.

**About AstraZeneca in Oncology**

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing 
portfolio of new medicines that has the potential to transform patients’ lives and
the Company’s future. With at least six new medicines to be launched between 2014
and 2020 and a broad pipeline of small molecules and biologics in development, we
are committed to advance Oncology as one of AstraZeneca’s four Growth Platforms 
focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities,
we actively pursue innovative partnerships and investments that accelerate the delivery
of our strategy as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers
and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing
the development of personalised combinations, AstraZeneca has the vision to redefine
cancer treatment and one day eliminate cancer as a cause of death.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide.

Share on:
